ImmunityBio Executive and Leadership Team

Frank Jones, the Chairman & Chief Executive Officer at ImmunityBio, directs the overarching corporate strategy and operational execution. Jones guides the company's mission to develop groundbreaking immunotherapies and vaccines that enhance the body's natural defenses against cancer and infectious diseases. This leadership role involves steering the development of novel cell therapy platforms and immunotherapy treatments, aiming to provide more effective and accessible alternatives to current standards of care. Frank Jones ensures alignment across all departments, driving the company's pursuit of durable and safe disease protection. The Chairman & Chief Executive Officer's focus remains on advancing the pipeline, particularly ANKTIVA's established success in bladder cancer, and expanding its application to other oncology and infectious disease challenges. This strategic direction under Jones's guidance seeks to significantly reduce reliance on traditional, high-dose chemotherapy.

Enrique Diloné, the Chief Technology Officer at ImmunityBio, architects the technological infrastructure and innovation pipeline for next-generation therapies. Diloné oversees the research and development of the company's advanced immunotherapy and cell therapy platforms, ensuring their scientific integrity and potential for broad application. This involves driving the technological advancements necessary to bolster the natural immune system for combating cancers and infectious diseases. The Chief Technology Officer's responsibilities include translating complex scientific discoveries into scalable and effective treatment modalities. Enrique Diloné ensures that the company's technological capabilities support the goal of creating durable and safe immune responses. Under Diloné's leadership, the technology division focuses on enhancing the accessibility and efficacy of ImmunityBio's product candidates, positioning them as superior alternatives to existing treatments in oncology and infectious disease management.

Sarah Singleton, the Chief Communications Officer & Head of Patient Advocacy at ImmunityBio, shapes the company's external messaging and champions patient interests. Singleton directs strategic communication initiatives, ensuring clear and consistent dissemination of ImmunityBio's mission and scientific advancements to stakeholders, including patients, healthcare providers, and the broader public. This role is critical in building trust and understanding around the company's novel immunotherapies and vaccines. Sarah Singleton also leads patient advocacy efforts, fostering strong relationships with patient communities and integrating their perspectives into the company's development and commercialization strategies. The Chief Communications Officer & Head of Patient Advocacy's work ensures that the patient voice is central to ImmunityBio's efforts to provide accessible and effective treatments for cancers and infectious diseases. Singleton's leadership enhances the company's reputation and its commitment to improving patient outcomes.

Leonard Sender, the Chief Medical Officer, Liquid Tumors & Cell Therapy at ImmunityBio, spearheads clinical development and medical strategy for critical therapeutic areas. Sender oversees the design and execution of clinical trials for novel immunotherapies and cell therapies, focusing on liquid tumors and the company's advanced cell therapy platforms. This leadership role is pivotal in demonstrating the safety and efficacy of ImmunityBio's treatments, including ANKTIVA's success in non-muscle invasive bladder cancer. The Chief Medical Officer, Liquid Tumors & Cell Therapy's responsibilities extend to translating scientific insights into robust clinical evidence that supports regulatory approvals and market adoption. Leonard Sender ensures that clinical programs align with the company's goal of creating durable immune responses and providing superior alternatives to chemotherapy. Sender's medical expertise drives the advancement of treatments aimed at defeating cancers and infectious diseases.